Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -0.65% 7.60 7.50 7.70 7.65 7.40 7.65 114,135 09:41:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 21

Evgen Pharma Share Discussion Threads

Showing 8001 to 8023 of 8400 messages
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
DateSubjectAuthorDiscuss
03/4/2021
13:19
OK - thanks for the info that ARDS of any cause is being targeted by the STAR trial. That is helpful information.
diamondstar1
03/4/2021
13:07
Regarding strategy and medical/scientific expertise, isn't this why they've recruited the new CBO and are in the process of recruiting a CSO? Strategy is to prove up the data then sell/out-licence to big pharma, who have the funding to take it all the way as you said.
on target
03/4/2021
13:02
Http://evgen.com/wp-content/uploads/2019/04/STEM-Headline-Results-Webcast-25Mar19-FINAL.pdf
on target
03/4/2021
12:57
Https://www.thoracic.org/patients/lung-disease-week/2011/ards-week/general-info.php - Acute respiratory distress syndrome (ARDS) is defined as an acute process, which results in moderate to severe loss of lung function. - Approximately 150,000-200,000 Americans will be diagnosed with ARDS each year. Worldwide, that number is approximately 2.2 million - There is no known prevention for ARDS at the present time. Nor is there any known cure. ARDS patients are treated with supportive care, most often in the Intensive Care Unit. - Although ARDS is always a critical syndrome, more than half of the patients who are diagnosed with ARDS survive.
on target
03/4/2021
12:17
I’m still pessimistic on Evgen at the moment- till I see them sort out their development strategy and medical/scientific expertise. For example, in COVID-19 treatment - can anyone explain how SFX-01 will fit into the overall treatment regime or treatment guidelines for COVID-19? You’ve got large numbers of the population being treated with vaccines at the moment - what happens when herd immunity is achieved? You will have very little patients hospitalised with COVID-19 with ARDS. Moreover, emergency usage of monoclonal antibodies has been approved for use for treating people in the pre-hospital phase - to reduce the number of severe cases of COVID-19. Hence, in my mind, Evgen may even face a unique challenge of completing the STAR trial, as the number of COVID hospitalisations decrease, and the number of potential ARDS cases decreases. Even if the interims for STAR-trial are positive, and they do somehow complete enrolling 300 patients (example, in 1 years time when COVID pandemic is largely over), they still may likely need to complete a larger Ph3 trial, I am assuming? Then there is a question how SFX-01 will be able to compete with 1126 other drugs being developed for COVID-19 at present. Essentially, it is the big Pharma who have the huge pockets and abundant expertise who are succeeding in this game e.g. Pfizer, AstraZeneca, J&J. Because adequate funding means that they can accelerate development plans, and get drugs approved in a timely manner. With regards to the cancer space. Evgen have not succeeded in the breast cancer space for the past 5 years. What evidence do we have that they possess the knowledge and experience to succeed in glioma, which has new therapies such as monoclonal antibodies and conventional radiotherapy?
diamondstar1
02/4/2021
15:53
As well as SFX-01's focus on Nrf2 for Covid/Ards, its influence over STAT3 could also be of significance in proving efficacy. Gla ;-) Contribution of STAT3 to the pathogenesis of COVID-19 Highlights STAT-3 can be activated by numerous cytokines during COVID-19. STAT-3 is hyper-activated and can play a central role in COVID-19 pathogenesis. Activated STAT-3 can promote hyper-inflammation, lung fibrosis and thrombosis. Activated STAT-3 promotes lymphopenia and impairs anti-virus immune responses. STAT3 may be a potential therapeutic target for the treatment of COVID-19. hTtps://www.sciencedirect.com/science/article/pii/S088240102100108X
moneymunch
02/4/2021
10:37
We're also awaiting news on Evgen's new cancer target related to SFX-01's influence over the SHP2 pathway.....a RED HOT Oncology target for lucrative licensing deals....here's a few recent examples. Gla ;-) TOKYO, Japan; 13 January, 2021 Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary. htTps://www.pharmiweb.com/press-release/2021-01-13/taiho-and-astex-extend-strategic-oncology-collaboration-with-msd-granting-exclusive-license-to-shp2-program ................... Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient Successful additions of ERAS-601 and ERAS-007, potential best-in-class inhibitors of SHP2 and ERK, respectively, enable “MAPK Clamp” approach to shut down RAS/MAPK pathway Erasca doses first patient in FLAGSHP-1 study, Erasca’s first clinical trial January 06, 2021 08:00 AM Eastern Standard Time SAN DIEGO--(BUSINESS WIRE)--Erasca, a company whose mission is to erase cancer, announced the expansion of its pipeline of precision oncology therapies via two exclusive, worldwide agreements directed at targeting critical upstream and downstream nodes in the RAS/MAPK signaling cascade, one of the most frequently mutated oncogenic pathways in cancer. ERAS-601, a potential best-in-class inhibitor of the Src homology region 2 domain-containing phosphatase-2 (SHP2), was licensed from NiKang Therapeutics, Inc. ERAS-007, a potential best-in-class inhibitor of the extracellular signal-regulated kinase (ERK), the most distal node of the RAS/MAPK pathway, was acquired from ASN Product Development, Inc., a wholly owned subsidiary of Asana BioSciences, LLC. hTtps://www.businesswire.com/news/home/20210106005241/en/Erasca-Unveils-Its-First-Strategy-to-Erase-Cancer-Accelerated-by-Expansion-of-Precision-Oncology-Pipeline-and-Dosing-of-First-Patient ....................... October 26, 2020 News briefing: AstraZeneca follows Amgen down KRAS/SHP2 combo path; Revolution Medicines is adding AstraZeneca to its roster of clinical collaborators, lending its lead drug, RMC-4630, for a study pairing it with the pharma giant’s KRAS G12C program. AstraZeneca will sponsor and conduct the study once its now preclinical drug is ready for human studies, an arrangement similar to the deal Revolution has with Amgen on sotorasib. Drug combinations are likely to be critical for defeating inherent drug resistance mechanisms exploited by RAS-addicted cancers, CEO Mark Goldsmith said in a statement. An allosteric SHP2 inhibitor, RMC-4630 attracted Sanofi for a partnership that involved $50 million upfront, 80% of the R&D cost, and a swath of milestones adding up to $520 million. Revolution is also working on a pipeline from its buyout of Warp Drive Bio of drugs that directly inhibit oncogenic RAS(ON) variants, including KRASG12C(ON) and KRASG12D(ON). htTps://endpts.com/news-briefing-astrazeneca-follows-amgen-down-kras-shp2-combo-path-vallon-pharmaceuticals-files-for-17-million-ipo/ ...................... December 21, 2020 Financing China Months af­ter strik­ing SHP2 deal with Ab­b­Vie, Ja­co­bio pulls in $174M+ from Hong Kong IPO The sea­soned crew at Ja­co­bio has raised $174.1 mil­lion on its HKEX de­but, fu­elling a pipeline an­chored by two Ab­b­Vie-part­nered al­losteric SHP2 in­hibitors. .............. AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors News provided by AbbVie Jun 01, 2020, 01:00 ET Share this article NORTH CHICAGO, Ill. and BEIJING, June 1, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 is an important protein mediator of cellular signaling through RAS/MAP kinase pathway. Many tumors have genetic mutations, driving abnormal cancer cell growth which relies on SHP2 activity. SHP2 also plays a key role to control cytokine production and immune cell response. Therefore, inhibition of SHP2 is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumor activities. Jacobio's early clinical stage SHP2 assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2 activity. "Identifying promising new targeted approaches for solid tumor patients is a high priority for us," said Mohit Trikha, Ph.D., vice president and head, early development oncology and Bay Area site head, AbbVie. "Jacobio's SHP2 program has the potential to treat cancer patients across many tumor types. By targeting a key node in both cancer and immune cell signaling pathways, SHP2 inhibition, both as a monotherapy and potentially in combination with other agents, may rapidly advance new treatment options for cancer patients." "We are excited to expand our efforts in global development of delivering breakthrough innovation to not just Chinese, but global patients with cancer," said Yinxiang Wang, Ph.D., CEO and Chairman, Jacobio. "We look forward to a productive collaboration with AbbVie focused on rapidly advancing this novel SHP2 first-in-class therapy as a new approach for multiple cancer types. I am confident that this partnership will strengthen our R&D capabilities and ultimately bring benefits to cancer patients." Under the terms of the agreement, AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. Upon completion, AbbVie will assume global development and commercialization responsibilities. Jacobio has an option, exercisable before the initiation of registrational trials, to exclusively develop and commercialize the SHP2 program in mainland China, Hong Kong, and Macau. Financial terms were not disclosed and the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. ........................... Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971 December 14, 2020 Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones, plus royalties on global net product sales hTtps://www.globenewswire.com/news-release/2020/12/14/2144322/0/en/Relay-Therapeutics-Announces-a-Worldwide-License-and-Collaboration-Agreement-with-Genentech-for-RLY-1971.html
moneymunch
02/4/2021
10:20
Yes indeed Bumpa, SFX-01 has been shown to directly modulate at least three unrelated mechanistic targets; Nrf2, STAT3 and more recently SHP2, all associated with multiple disease targets and all attracting huge interest from Big pharma in their therapeutic potential and all under numerous scientific research, evaluation and clinical trials and a raft of lucrative licensing deals to accelerate development. Sooner or later true and fair value will prevail, but near term it would appear the market is awaiting Prof Chalmers preliminary efficacy data from the Covid/ARDS trial...positive data will propel Evgen's prospects and potential towards global investor focus and appreciation imho. Gl ;-) "Focus on breast cancer, acute respiratory distress including COVID, glioma and other cancers, SFX-01 has three molecular targets, STAT3, Nrf2 and SHP2."
moneymunch
02/4/2021
09:15
Too many people can’t look past the covid trial - because frankly all they can understand is ‘solve covid and I might get rich’. I’m hoping SFX-01 is the key to unlock inflammatory responses in the body, period. Understand the role of inflammation in chronic disease, and then you’ll appreciate the real prize and the true scale of potential.
bumpa33
02/4/2021
09:14
Star-Covid19 Study Strong evidence that Nrf2 activation is relevant in acute respiratory distress syndrome(ARDS). The Nrf2 pathway has been found to be suppressed in lung biopsies from COVID19 patients Sulforaphane is one of very few activators of the transcription factor Nrf2- via suppression of KEAP1, allowing Nrf2 to restore redox homeostasis, protect against oxidative stress and provide suppression of inflammatory mediators SFX-01 is the only synthetic druggable form of sulforaphane suitable for clinical trials and was selected for the COVID study STAR-COVID19 study is sponsored by the University of Dundee and funded byLifeArc The study is recruiting patients with ARDS of any origin, is not limited to COVID-19 positive patients. ARDS is a long-standing serious health problem and will remain so long after the current pandemic subsides. Pre-COVID there were 190,000 patients and 30,000 ICU beds p.a. utilised in the USA alone
moneymunch
02/4/2021
08:50
Every chance that the potency of SFX-01 and its influence over NRF2 and oxidative stress could be of benefit in treating Covid/ARDS. Gla; -)
moneymunch
02/4/2021
08:15
Can Activation of NRF2 Be a Strategy against COVID-19? Highlights The host inflammatory response is a crucial determinant of disease outcome and correlates with disease severity in SARS-CoV-2-induced infection, for which there is no treatment to date. Activation of transcription factor nuclear factor erythroid 2 p45-related factor 2 (NRF2) promotes resolution of inflammation and, in parallel, restores cellular redox and protein homeostasis, and facilitates tissue repair. NRF2 can be activated by pharmacological inducers that target Kelch-like ECH-associated protein 1 (KEAP1), the principal negative regulator of NRF2. The available information on pharmacokinetics, pharmacodynamics, safety, and efficacy for the NRF2 activators sulforaphane and bardoxolone methyl (currently in advanced clinical trials for other disease indications) in humans makes them excellent candidates for testing in randomized clinical trials in COVID-19. hTtps://www.sciencedirect.com/science/article/pii/S0165614720301656
moneymunch
02/4/2021
08:11
SFX-01 was selected from over 130 drug candidates by LifeArc and University of Dundee for Covid/ARDS patient trials, there's a raft of scientific research that highlights Sulforaphanes therapeutic potential over multiple disease targets including respiratory inflammation disease associated with Covid/ARDS and and so no shot in the dark and every chance that Prof Chalmers could report positive preliminary efficacy data, expected Q2, which would be a complete game changer and totally transformational for Evgen's prospects and potential going forward. Gla Holders...news could drop at anytime. ;-) ................................. 5 CONCLUSIONS The severity of COVID‐19 pandemic is mainly based on two relevant aspects: high degree of contagiousness and high frequency of massive inflammatory reactions, which lead to serious and life‐threatening disease outcomes. In this perspective, the pathophysiological role of the gasotransmitter H2S provides opportunities for additional investigation. This endogenous mediator can modulate the inflammatory response in a complex regulation of the cytokine cascade. Moreover, preliminary studies point to a role of H2S in regulating the host response to viral infections (Yang, 2020). Such evidence provides a strong case for the potential antiviral benefits offered by different classes and chemotypes of H2S donor molecules as therapeutic agents, as recently proposed also by other pioneering hypotheses (Evgen'ev & Frenkel, 2020; Yang, 2020). Several compounds already in clinical development for other therapeutic indications, such as SG1002 or sulforaphane, can be viewed as potential high‐value candidates for rapid repurposing for antiviral therapy against COVID‐19. hTtps://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15230
moneymunch
02/4/2021
00:06
htTp://www.srxa.com/bousquet.html
bumpa33
01/4/2021
19:12
Fingers crossed that Huw and Prof Chalmers have got a basket of Golden Easter Eggs to share with us.:-)
moneymunch
01/4/2021
17:42
Indeed, do we know anyone doing a sort of ‘supercharged kimchi’ trial?!
bumpa33
01/4/2021
17:40
Sulforaphane (or its precursor) in the cabbage in kimchi activates the NRF2 pathway and alleviates COVID-19 symptoms eh? Interesting, and that's despite the lactic fermentation which I've read reduces the amounts. Wonder what it would do if it was given to patients in a concentrated pill form? Someone should do a clinical trial..
on target
01/4/2021
17:35
htTp://www.koreabiomed.com/news/articleView.html?idxno=10835 Someone have a word with James and get the garlic & ginger out :)
bumpa33
31/3/2021
20:15
Some chunky late reported trades as usual, certainly suggests shares are being accumulated on the cheap.....Q2 fast approaching, plenty of action anticipated. Gla :-)
moneymunch
30/3/2021
21:36
Nico must have a mate with a rubber.
bocker01
30/3/2021
21:14
Haha That's not me bockerI'm certainly not bearish at this price I just think directors should've bought more stockIt's a buy at this EV ,just not a conviction buy
nico115
30/3/2021
21:04
Lol, yep a deletion, now why does that happen???
moneymunch
30/3/2021
20:09
Oops there two of them. Thumb must have got in the way
bocker01
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210513 10:06:13